Juan M. Lozano-Gil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan M. Lozano-Gil has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Victoriano Mulero
Departamento de Biología Celular e Histología, Facultad de Biología, Universidad de Murcia, Spain
5 shared publications - Diana García-Moreno
Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Spain
4 shared publications - Maria Luisa Cayuela
Grupo de Telomerasa, Cáncer y Envejecimiento, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain
4 shared publications - Sylwia D. Tyrkalska
Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Murcia, Spain
4 shared publications - Lola Rodríguez-Ruiz
Departamento de Biología Celular e Histología, Facultad de Biología, Universidad de Murcia, Murcia, Spain
3 shared publications - Alicia Martínez-López
Instituto Murciano de Investigación Biosanitaria (IMIB-Pascual Parrilla), Murcia, Spain
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Springer Nature in Research Square
GAPDH nuclear signaling regulates neutrophil migration and inflammatory skin responses
Neutrophils are the most abundant leukocytes and key regulators of tissue homeostasis and disease. Here we show that inhibiting Gapdh nuclear translocation limits neutrophil infiltration into inflamed skin, reduces their motility, and decreases keratinocyte hyperproliferation and cell death in a zebrafish model of skin inflammation. Wild-type Gapdh expression in neutrophils, but not a nuclear-translocation–deficient mutant, exacerbated inflammation. Pharmacological inhibition of GAPDH nuclear translocation also attenuated pathology-associated markers in human organotypic 3D skin models of inflammation. In psoriasis lesions, GAPDH levels were elevated with altered localization. Single-cell RNA-seq revealed that Gapdh nuclear translocation regulates a subset of inflammation-induced genes in neutrophils, including il4. Mechanistically, Gapdh enhances il4 transcription by promoting H3K27 acetylation at its promoter, whereas pharmacological inhibition of this pathway restores basal levels. Consistently, Il4 deficiency alleviated inflammation. These findings identify a conserved, non-canonical GAPDH signaling pathway that orchestrates chronic skin inflammation and represents a potential therapeutic target.
- 11 August 2026
- Published by Springer Nature in Research Square
Open AccessGAPDH nuclear signaling regulates neutrophil migration and inflammatory skin responses
Neutrophils are the most abundant leukocytes and key regulators of tissue homeostasis and disease. Here we show that inhibiting Gapdh nuclear translocation limits neutrophil infiltration into inflamed skin, reduces their motility, and decreases keratinocyte hyperproliferation and cell death in a zebrafish model of skin inflammation. Wild-type Gapdh expression in neutrophils, but not a nuclear-translocation–deficient mutant, exacerbated inflammation. Pharmacological inhibition of GAPDH nuclear translocation also attenuated pathology-associated markers in human organotypic 3D skin models of inflammation. In psoriasis lesions, GAPDH levels were elevated with altered localization. Single-cell RNA-seq revealed that Gapdh nuclear translocation regulates a subset of inflammation-induced genes in neutrophils, including il4. Mechanistically, Gapdh enhances il4 transcription by promoting H3K27 acetylation at its promoter, whereas pharmacological inhibition of this pathway restores basal levels. Consistently, Il4 deficiency alleviated inflammation. These findings identify a conserved, non-canonical GAPDH signaling pathway that orchestrates chronic skin inflammation and represents a potential therapeutic target.
- Open Access
- 21 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8904
Ninjurins regulate hematopoietic stem cell amplification through canonical WNT signaling independent of plasma membrane rupture
- 21 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8904
Open AccessNinjurins regulate hematopoietic stem cell amplification through canonical WNT signaling independent of plasma membrane rupture
- Open Access
- 9 January 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (2) , 702-724
TKI-mediated inhibition of NLRP1 inflammasome restores erythropoiesis in DBA syndrome
Diamond-Blackfan anemia syndrome (DBAS) is marked by defective erythropoiesis caused by impaired ribosome biogenesis and aberrant signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome affects erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective erythropoiesis by inhibiting NLRP1 inflammasome activation. In K562 cells, nilotinib suppresses the ZAKα/P38/NLRP1/CASP1 axis, leading to increased GATA1 levels and upregulation of key erythroid genes. These effects were validated in human CD34⁺ hematopoietic stem and progenitor cells (HSPCs) and zebrafish models, where nilotinib, imatinib, and dasatinib promoted erythropoiesis while reducing caspase-1 activity. In Rps19-deficient zebrafish, RPS19-deficient human HSPCs, and HSPCs from DBAS patients, TKIs rescued erythroid differentiation and restored hemoglobin levels. Our findings highlight that targeting the NLRP1 inflammasome with TKIs may provide a novel therapeutic strategy for DBAS and other ribosomopathies.
- 9 January 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (2) , 702-724
Open AccessTKI-mediated inhibition of NLRP1 inflammasome restores erythropoiesis in DBA syndrome
Diamond-Blackfan anemia syndrome (DBAS) is marked by defective erythropoiesis caused by impaired ribosome biogenesis and aberrant signaling. Here, we investigate how ribosomal stress-induced activation of the NLRP1 inflammasome affects erythroid differentiation in DBAS. We demonstrate that FDA/EMA-approved tyrosine kinase inhibitors (TKIs) effectively mitigate defective erythropoiesis by inhibiting NLRP1 inflammasome activation. In K562 cells, nilotinib suppresses the ZAKα/P38/NLRP1/CASP1 axis, leading to increased GATA1 levels and upregulation of key erythroid genes. These effects were validated in human CD34⁺ hematopoietic stem and progenitor cells (HSPCs) and zebrafish models, where nilotinib, imatinib, and dasatinib promoted erythropoiesis while reducing caspase-1 activity. In Rps19-deficient zebrafish, RPS19-deficient human HSPCs, and HSPCs from DBAS patients, TKIs rescued erythroid differentiation and restored hemoglobin levels. Our findings highlight that targeting the NLRP1 inflammasome with TKIs may provide a novel therapeutic strategy for DBAS and other ribosomopathies.
- Open Access
- 8 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Programmed cell death pathways coordinate neutrophil and macrophage clearance in zebrafish and are differentially exploited by Salmonella Typhimurium
Programmed cell death (PCD) is essential for immune cell homeostasis and host defense, yet its role in neutrophil and macrophage elimination during bacterial infections remains poorly understood. Using the zebrafish model, which offers unique in vivo imaging and genetic manipulation advantages, we dissected the contribution of pyroptosis, apoptosis, and necroptosis to the regulation of neutrophil and macrophage fate during homeostasis and infection with Salmonella enterica serovar Typhimurium (ST). Under basal conditions, all three PCD pathways cooperated to control immune cell turnover. Upon infection, zebrafish larvae mounted a type III secretion system (T3SS)-independent emergency myelopoietic response that increased myeloid cell numbers. However, the pathogen rapidly counteracted this response by promoting neutrophil death through Nlrp3-mediated pyroptosis and Caspase-3-dependent apoptosis, and macrophage killing via Ripk1-dependent necroptosis—both driven by its T3SS. While blocking pyroptosis prevented neutrophil loss, it also increased host susceptibility due to impaired bacterial clearance, whereas inhibition of apoptosis or necroptosis enhanced resistance, as these pathways are dispensable for controlling infection. These findings demonstrate how ST exploits distinct PDC mechanisms to evade innate immunity and underscore their differential potential as therapeutic targets in intracellular bacterial infections.
- 8 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessProgrammed cell death pathways coordinate neutrophil and macrophage clearance in zebrafish and are differentially exploited by Salmonella Typhimurium
Programmed cell death (PCD) is essential for immune cell homeostasis and host defense, yet its role in neutrophil and macrophage elimination during bacterial infections remains poorly understood. Using the zebrafish model, which offers unique in vivo imaging and genetic manipulation advantages, we dissected the contribution of pyroptosis, apoptosis, and necroptosis to the regulation of neutrophil and macrophage fate during homeostasis and infection with Salmonella enterica serovar Typhimurium (ST). Under basal conditions, all three PCD pathways cooperated to control immune cell turnover. Upon infection, zebrafish larvae mounted a type III secretion system (T3SS)-independent emergency myelopoietic response that increased myeloid cell numbers. However, the pathogen rapidly counteracted this response by promoting neutrophil death through Nlrp3-mediated pyroptosis and Caspase-3-dependent apoptosis, and macrophage killing via Ripk1-dependent necroptosis—both driven by its T3SS. While blocking pyroptosis prevented neutrophil loss, it also increased host susceptibility due to impaired bacterial clearance, whereas inhibition of apoptosis or necroptosis enhanced resistance, as these pathways are dispensable for controlling infection. These findings demonstrate how ST exploits distinct PDC mechanisms to evade innate immunity and underscore their differential potential as therapeutic targets in intracellular bacterial infections.
- Open Access
- 19 November 2025
- Published by Wiley in Immunological Reviews
- Vol. 336 (1) , e70077
Ontogenetic Diversification of Type 2 Conventional Dendritic Cells in the Bone Marrow: A Central Logic for Peripheral Immunity
Type 2 conventional dendritic cells (cDC2s) are central orchestrators of adaptive immunity. While historically considered a single population shaped by local microenvironments, recent evidence indicates that cDC2s comprise developmentally distinct subsets—cDC2As and cDC2Bs—with divergent ontogeny, tissue distribution, and immune functions. This review synthesizes current advances in the identification, differentiation, and functional characterization of these cDC2 subsets, with a focus on data supporting an early bifurcation at the level of bone marrow progenitors. We highlight how transcription factors such as TCF4 (and RBPJ) and KLF4 delineate cDC2A and cDC2B fates, respectively, and how subset‐specific localization within tissues may amplify their distinct roles in immunity. We propose that early cDC2 diversification reflects a broader principle of central immune preconfiguration, in which the bone marrow senses peripheral immunological states and anticipates tissue‐specific demands through progenitor programming. This hypothetical model redefines cDC2s not merely as adaptable responders to local cues, but as a paradigm for how immune output can be systemically preconfigured. As such, they offer a powerful lens through which to study how development and function intersect across immunity. Recent findings suggest that the ontogenetic logic in mouse cDC2 development may extend to humans, offering meaningful avenues for translational exploration.
- 19 November 2025
- Published by Wiley in Immunological Reviews
- Vol. 336 (1) , e70077
Open AccessOntogenetic Diversification of Type 2 Conventional Dendritic Cells in the Bone Marrow: A Central Logic for Peripheral Immunity
Type 2 conventional dendritic cells (cDC2s) are central orchestrators of adaptive immunity. While historically considered a single population shaped by local microenvironments, recent evidence indicates that cDC2s comprise developmentally distinct subsets—cDC2As and cDC2Bs—with divergent ontogeny, tissue distribution, and immune functions. This review synthesizes current advances in the identification, differentiation, and functional characterization of these cDC2 subsets, with a focus on data supporting an early bifurcation at the level of bone marrow progenitors. We highlight how transcription factors such as TCF4 (and RBPJ) and KLF4 delineate cDC2A and cDC2B fates, respectively, and how subset‐specific localization within tissues may amplify their distinct roles in immunity. We propose that early cDC2 diversification reflects a broader principle of central immune preconfiguration, in which the bone marrow senses peripheral immunological states and anticipates tissue‐specific demands through progenitor programming. This hypothetical model redefines cDC2s not merely as adaptable responders to local cues, but as a paradigm for how immune output can be systemically preconfigured. As such, they offer a powerful lens through which to study how development and function intersect across immunity. Recent findings suggest that the ontogenetic logic in mouse cDC2 development may extend to humans, offering meaningful avenues for translational exploration.
- Open Access
- 7 September 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (10) , e18142
ZAKα/P38 kinase signaling pathway regulates hematopoiesis by activating the NLRP1 inflammasome
Chronic inflammatory diseases are associated with hematopoietic lineage bias, including neutrophilia and anemia. We have recently identified that the canonical inflammasome mediates the cleavage of the master erythroid transcription factor GATA1 in hematopoietic stem and progenitor cells (HSPCs). We report here that genetic inhibition of Nlrp1 resulted in reduced number of neutrophils and increased erythrocyte counts in zebrafish larvae. We also found that the NLRP1 inflammasome in human cells was inhibited by LRRFIP1 and FLII, independently of DPP9, and both inhibitors regulated hematopoiesis. Mechanistically, erythroid differentiation resulted in ribosomal stress‐induced activation of the ZAKα/P38 kinase axis which, in turn, phosphorylated and promoted the assembly of NLRP1 in both zebrafish and human. Finally, inhibition of Zaka with the FDA/EMA‐approved drug Nilotinib alleviated neutrophilia in a zebrafish model of neutrophilic inflammation and promoted erythroid differentiation and GATA1 accumulation in K562 cells. In conclusion, our results reveal that the NLRP1 inflammasome regulates hematopoiesis and pave the way to develop novel therapeutic strategies for the treatment of hematopoietic alterations associated with chronic inflammatory and rare diseases.
- 7 September 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (10) , e18142
Open AccessZAKα/P38 kinase signaling pathway regulates hematopoiesis by activating the NLRP1 inflammasome
Chronic inflammatory diseases are associated with hematopoietic lineage bias, including neutrophilia and anemia. We have recently identified that the canonical inflammasome mediates the cleavage of the master erythroid transcription factor GATA1 in hematopoietic stem and progenitor cells (HSPCs). We report here that genetic inhibition of Nlrp1 resulted in reduced number of neutrophils and increased erythrocyte counts in zebrafish larvae. We also found that the NLRP1 inflammasome in human cells was inhibited by LRRFIP1 and FLII, independently of DPP9, and both inhibitors regulated hematopoiesis. Mechanistically, erythroid differentiation resulted in ribosomal stress‐induced activation of the ZAKα/P38 kinase axis which, in turn, phosphorylated and promoted the assembly of NLRP1 in both zebrafish and human. Finally, inhibition of Zaka with the FDA/EMA‐approved drug Nilotinib alleviated neutrophilia in a zebrafish model of neutrophilic inflammation and promoted erythroid differentiation and GATA1 accumulation in K562 cells. In conclusion, our results reveal that the NLRP1 inflammasome regulates hematopoiesis and pave the way to develop novel therapeutic strategies for the treatment of hematopoietic alterations associated with chronic inflammatory and rare diseases.